HiFiBiO Therapeutics

📍 Cambridge, United States🗓 Founded 2013👥 73 employees💰 Last funded Jun 2021
Biotechnology🌐 hifibio.com
Website LinkedIn
HiFiBiO Therapeutics is a clinical-stage global biotech pioneering a unique high-resolution translational solution (DIS®, Drug Intelligence Science) to enhance the probability of success for immunotherapies. DIS® combines unique single-cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers. With DIS®, HiFiBiO gains an unprecedented understanding of immune modulation in human diseases driving a robust clinical pipeline of transformative immunotherapies. Additionally, HiFiBiO has partnered with major multinational pharmaceutical and biotech companies applying its innovative DIS® approach. HiFiBiO Therapeutics is headquartered in Cambridge, MA with additional operations in Paris, France, Hong Kong, Shanghai, and Hangzhou, China.
2
Total investors
0
Early stage
0
Mid stage
2
Late stage
2013
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
China
2
Frequently asked questions
Who invested in HiFiBiO Therapeutics?
HiFiBiO Therapeutics has 2 investors on record on gritt.io and 2 late-stage investors.
When did HiFiBiO Therapeutics last raise funding?
The most recent investment in HiFiBiO Therapeutics recorded on gritt.io was in June 2021.
When was HiFiBiO Therapeutics founded?
HiFiBiO Therapeutics was founded in 2013.
What industry is HiFiBiO Therapeutics in?
HiFiBiO Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is HiFiBiO Therapeutics based?
HiFiBiO Therapeutics is headquartered in Cambridge, United States.